Advertisement

Topics

Pembrolizumab Demonstrates Increased Overall Survival in Metastatic NSCLC Patients

10:00 EST 6 Nov 2017 | OncoTherapy Network

Data presented at the recent World Conference on Lung Cancer show that pembrolizumab improves overall survival in patients with metastatic non-small cell lung cancer whose tumors express high levels of PD-L1.

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Pembrolizumab Demonstrates Increased Overall Survival in Metastatic NSCLC Patients

NEXT ARTICLE

More From BioPortfolio on "Pembrolizumab Demonstrates Increased Overall Survival in Metastatic NSCLC Patients"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.